148 related articles for article (PubMed ID: 22020315)
1. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.
Chung V; Heath EI; Schelman WR; Johnson BM; Kirby LC; Lynch KM; Botbyl JD; Lampkin TA; Holen KD
Cancer Chemother Pharmacol; 2012 Mar; 69(3):733-41. PubMed ID: 22020315
[TBL] [Abstract][Full Text] [Related]
2. GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy.
Tang JC; Wu K; Zheng X; Xu M; Dai Y; Wei SS; Cai XJ
Chin Med J (Engl); 2019 Feb; 132(3):311-318. PubMed ID: 30681497
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Mayes PA; Degenhardt YY; Wood A; Toporovskya Y; Diskin SJ; Haglund E; Moy C; Wooster R; Maris JM
Int J Cancer; 2013 Feb; 132(3):E149-57. PubMed ID: 22948716
[TBL] [Abstract][Full Text] [Related]
4. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
5. Pgp efflux pump decreases the cytostatic effect of CENP-E inhibitor GSK923295.
Tcherniuk SO; Oleinikov AV
Cancer Lett; 2015 May; 361(1):97-103. PubMed ID: 25725449
[TBL] [Abstract][Full Text] [Related]
6. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
Sun Y; Yang L; Hao X; Liu Y; Zhang J; Ning Z; Shi Y
J Hematol Oncol; 2019 Jan; 12(1):9. PubMed ID: 30642372
[TBL] [Abstract][Full Text] [Related]
8. Cenp-E inhibitor GSK923295: Novel synthetic route and use as a tool to generate aneuploidy.
Bennett A; Bechi B; Tighe A; Thompson S; Procter DJ; Taylor SS
Oncotarget; 2015 Aug; 6(25):20921-32. PubMed ID: 26320186
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.
LoRusso P; Venkatakrishnan K; Chiorean EG; Noe D; Wu JT; Sankoh S; Corvez M; Sausville EA
Invest New Drugs; 2014 Feb; 32(1):160-70. PubMed ID: 23817974
[TBL] [Abstract][Full Text] [Related]
10. Identification of benzo[d]pyrrolo[2,1-b]thiazole derivatives as CENP-E inhibitors.
Yamane M; Sawada JI; Ogo N; Ohba M; Ando T; Asai A
Biochem Biophys Res Commun; 2019 Nov; 519(3):505-511. PubMed ID: 31530389
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
12. Distinct Mechanisms of Resistance to a CENP-E Inhibitor Emerge in Near-Haploid and Diploid Cancer Cells.
Pisa R; Phua DYZ; Kapoor TM
Cell Chem Biol; 2020 Jul; 27(7):850-857.e6. PubMed ID: 32442423
[TBL] [Abstract][Full Text] [Related]
13. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS
Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453
[TBL] [Abstract][Full Text] [Related]
18. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
20. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
Nemunaitis JJ; Small KA; Kirschmeier P; Zhang D; Zhu Y; Jou YM; Statkevich P; Yao SL; Bannerji R
J Transl Med; 2013 Oct; 11():259. PubMed ID: 24131779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]